SCHEMBL7602348

SCHEMBL7602348

CC(C)(C)c1ccc(-n2c3ccccc3c3ccccc32)cc1-c1c2ccccc2c(-c2ccccc2)c2ccccc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.41
L3MBTL1 Q9Y468 3/20 0.41
ATM Q13315 1/20 0.41
KMT2A Q03164 3/20 0.39
LMNA P02545 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
RCE1 Q9Y256 1/20 0.33
HSD17B10 Q99714 1/20 0.33
EDNRB P24530 1/20 0.32
EDNRA P25101 1/20 0.32
GAA P10253 1/20 0.32
PPARG P37231 1/20 0.31
ACHE P22303 1/20 0.31
HDAC4 P56524 1/20 0.31
IL1R1 P14778 1/20 0.31
ALDH1A1 P00352 2/20 0.30
PKM P14618 1/20 0.30
HKDC1 Q2TB90 1/20 0.30
MEN1 O00255 1/20 0.30
MAPT P10636 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7600841 0.89 KDM4E (0.41) KDM4EL3MBTL1ATMKMT2ALMNA
SCHEMBL10100816 0.85 KDM4E (0.47) KDM4EL3MBTL1ATMPPARGHDAC4
SCHEMBL7601617 0.83 KDM4E (0.43) KDM4EL3MBTL1ATMKMT2ALMNA
SCHEMBL7600811 0.82 KDM4E (0.44) KDM4EL3MBTL1ATMKMT2ALMNA
SCHEMBL7602353 0.81 KDM4E (0.40) KDM4EL3MBTL1ATMKMT2ALMNA
SCHEMBL7605746 0.79 KDM4E (0.44) KDM4EL3MBTL1ATMKMT2ALMNA
SCHEMBL13428282 0.78 L3MBTL1 (0.53) KDM4EL3MBTL1ATMKMT2ALMNA
SCHEMBL1925373 0.78 L3MBTL1 (0.53) KDM4EL3MBTL1ATMKMT2ALMNA
SCHEMBL12928330 0.78 L3MBTL1 (0.53) KDM4EL3MBTL1ATMKMT2ALMNA
SCHEMBL12853070 0.77 L3MBTL1 (0.44) KDM4EL3MBTL1ATMKMT2AEDNRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8183793-B2 Method for synthesizing anthracene derivative and anthracene derivative, light emitting element, light emitting device, electronic device SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2012-05-22 US disclosed
US-20110050118-A1 METHOD FOR SYNTHESIZING ANTHRACENE DERIVATIVE AND ANTHRACENE DERIVATIVE, LIGHT EMITTING ELEMENT, LIGHT EMITTING DEVICE, ELECTRONIC DEVICE SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2011-03-03 US disclosed
US-20080107918-A1 METHOD FOR SYNTHESIZING ANTHRACENE DERIVATIVE AND ANTHRACENE DERIVATIVE, LIGHT EMITTING ELEMENT, LIGHT EMITTING DEVICE, ELECTRONIC DEVICE SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2008-05-08 US disclosed
US-20080107918-A1 METHOD FOR SYNTHESIZING ANTHRACENE DERIVATIVE AND ANTHRACENE DERIVATIVE, LIGHT EMITTING ELEMENT, LIGHT EMITTING DEVICE, ELECTRONIC DEVICE SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2008-05-08 US disclosed
WO-2008026614-A1 METHOD FOR SYNTHESIZING ANTHRACENE DERIVATIVE AND ANTHRACENE DERIVATIVE, LIGHT EMITTING ELEMENT, LIGHT EMITTING DEVICE, ELECTRONIC DEVICE SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2008-03-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110050118-A1 METHOD FOR SYNTHESIZING ANTHRACENE DERIVATIVE AND ANTHRACENE DERIVATIVE, LIGHT EMITTING ELEMENT, LIGHT EMITTING DEVICE, ELECTRONIC DEVICE ALAD, CYP2C9, CYP1A1 KDM4E 2175/4885L3MBTL1 3456/4885ATM 527/4885
US-20080107918-A1 METHOD FOR SYNTHESIZING ANTHRACENE DERIVATIVE AND ANTHRACENE DERIVATIVE, LIGHT EMITTING ELEMENT, LIGHT EMITTING DEVICE, ELECTRONIC DEVICE ALAD, CYP2C9, CYP1A1 KDM4E 2175/4885L3MBTL1 3456/4885ATM 527/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.